Free Trial
→ How War with China Could Start in 128 Days (From Behind the Markets) (Ad)

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 7 of 15

Slide 7
Back to 6
Continue to 8
 
Back to 6
Continue to 8
 

Guardant Health (NASDAQ:GH)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
21 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$49.00 (9.0% Upside)

About Guardant Health

Guardant Health logoGuardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. More about Guardant Health
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/10/2025BarclaysLower Price TargetOverweight ➝ Overweight$60.00 ➝ $55.00
4/10/2025MizuhoInitiated CoverageOutperform$55.00
4/9/2025MizuhoUpgradeStrong-Buy
3/26/2025StephensReiterated RatingOverweight ➝ Overweight$55.00 ➝ $55.00
3/6/2025Morgan StanleyBoost Price TargetOverweight ➝ Overweight$42.00 ➝ $52.00
2/26/2025Piper SandlerBoost Price TargetOverweight ➝ Overweight$34.00 ➝ $50.00
2/24/2025ScotiabankBoost Price TargetSector Outperform ➝ Sector Outperform$47.00 ➝ $52.00
2/24/2025GuggenheimReiterated RatingBuy ➝ Buy$56.00 ➝ $56.00
2/24/2025Canaccord Genuity GroupBoost Price TargetBuy ➝ Buy$42.00 ➝ $60.00
2/21/2025The Goldman Sachs GroupBoost Price TargetBuy ➝ Buy$49.00 ➝ $56.00
Slide 7
Back to 6
Continue to 8
 

More From MarketBeat
Claim Your FREE Protection Guide
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...
American Alternative | Sponsored
7 High-Yield Dividend Stocks for Massive Passive Income in 2025
In volatile markets, it makes sense to own passive income-generating stocks. As we move into 2025, there are...
MarketBeat
Trump’s Top Secret $9 Trillion AI Superweapon
Jeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...
Brownstone Research | Sponsored
7 Best Stocks to Own Right Now
Today, we invite you to view our list of the seven best stocks to own for the next thirty days. Why is it w...
MarketBeat
My prediction is coming true
We've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...
InvestorPlace | Sponsored
7 Stocks Changing the World—and Making Investors Wealthy
Technology is evolving faster than ever. Disruptive technology that was seen as groundbreaking just a decade...
MarketBeat